Lonafarnib - Cyclolab
Alternative Names: SBECD-enabled LonafarnibLatest Information Update: 31 Dec 2024
Price :
$50 *
At a glance
- Originator Cyclolab
- Class Amides; Antineoplastics; Antivirals; Benzene derivatives; Halogenated hydrocarbons; Piperidines; Pyridines; Small molecules
- Mechanism of Action Farnesyltranstransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Progeria
Most Recent Events
- 31 Dec 2024 Chemical structure information added.
- 24 Jul 2024 Lonafarnib - Cyclolab is available for licensing as of 24 Jul 2024. https://cyclolab.hu/pipeline/ (Cyclolab pipeline, July 2024)
- 24 Jul 2024 Preclinical trials in Progeria in Hungary (PO) prior to July 2024 (Cyclolab pipeline, July 2024)